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approach for the detection of toxigenic Clostridium 
di[jcile strains compared with existing methods, patient 
selection may have been critical in obtaining these 
results. The conclusions were based on the results of 
toxin detection in fecal specimens from patients on 
specialized units whose stools were ‘weekly system- 
atically investigated’. This fact is inconsistent with the 
statement that diarrheal stool specimens were in- 
vestigated. Furthermore, despite the statement that 
consecutive stools were examined, the 7-nlonth total of 
548 was equivalent to only 18 specimens per week, a 
rather low figure. The study patients may well have 
differed markedly from symptomatic patients suspected 
of having C. dificile-associated disease (CDAL)) and 
would be more likely to have included individuals 
with asymptomatic carriage; this might explain the 
apparently poor performance of fecal toxin detection 
methods when compared with culture-based methods. 
Toxin may well have been absent from the stools of 
many patients, although they were harboring toxigenic 
strains. Treatment of C. dficile carriers is not widely 
recognized as being particularly useful. Presence of 
toxin in the stool specimens, however, has been shown 
to correlate more closely with clinical disease [2,3] and 
it would be worth comparing the standard method for 
fecal stool toxin detection (cytopathic effect on cell 
lines) with the authors’ method, to determine whether 
there are significant differences in detection rates when 
patients with clinically suspected CIIAI) are investi- 
gated. The results of fecal cytotoxin detection are 
given after incubation for 24 h but not after 48 h, 
which is the normal endpoint for the test. Also, 
unpublished work in our department indicates that 
detection of fecal cytotoxin in stools from symp- 
tomatic patients has a sensitivity of 70% after incubation 
for 6 h, reaching 96% by 24 h and 100% at 48 h. 
The authors have shown detailed clinical analysis 
for only 19 of 41 1 patients whose stools were examined 
to support a correlation between toxigenic strain 
detection and patient symptoms; also, more than one 
fecal specimen was included for some of these patients. 
How and why were only 19 patients selected? The 
claim that culture plus enzyme immunoassay (EIA) is 
better than fecal toxin detection, as some toxin negative 
stools came from patients whose charts were com- 
patible with CDAD, remains unproven. The authors 
state that the prevalence of the toxigenic carrier state 
was 13%; what does this mean and how was it 
calculated? 
The authors’ suggestion is that culture followed 
by EIA is a better method for determining clinically 
significant CDAD than fecal toxin detection by cyto- 
pathic effect. To ensure that this is the case, a more 
rigorous analysis of laboratory and clinical data is 
required. Rapid transport of fe4zal specimens to the 
laboratory will reduce the possibility of toxin degrada- 
tion in transit. Merely knowing 1:hat a toxigenic strain 
is present may not be particularly helpful, as it will be 
difficult to assess whether the patient is in the early 
stages of disease with very low tc’xin titers or is just an 
asymptomatic carrier. 
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Reply to the Letter to the Editor from Settle and Wilcox 
We appreciate the interest and the comments of Settle 
and Wilcox with regard to our recent article. We agree 
with these colleagues that results might have been 
different if we had used other criteria for selecting the 
stool specimens. However, our goal was to evaluate a 
new approach in a specific hospital setting where the 
laboratory has to deal with a 101: of hospital-acquired 
diarrhea from patients in oncology, hematology or 
intensive care units. This is a typ-ical situation encoun- 
tered in many laboratories. As pointed out in our 
discussion, the interpretation of- some of our results 
where a toxigenic isolate was detected, whereas there 
was no toxin detected directly in stools, is controversial. 
We believe, however, that a hospitalized patient suffer- 
ing from diarrhea (as was the c;.se in all our selected 
patients) and excreting a toxigenic Clostridiurn dfjcile 
strain should be identified, at  least to allow enteric 
isolation and thus to avoid an epidemic. From this 
single viewpoint, our approach allows a significant 
improvement. 
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Some of their criticisms are probably due to a lack 
of detail in our text. We do receive systematic weekly 
specimens from specific units for bacterial screening, 
but, in our study, we only selected diarrheal stools. As 
stated in Material and Methods, cells for fecal cytotoxin 
detection were examined after overnight and 48-h 
incubation. We observed 50 positive cases; all were 
already positive at  the first reading. No additional 
specimen was positive after 48 h. Fifty-three of the 41 1 
patients had at least one stool positive for a toxigenic 
isolate, giving a prevalence of 13%. 
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I an1 writing about the contents of Supplement 1 to 
Volume 2 (December 1996 [l]). The article by 
Goldstein and his colleagues (p. S40) was excellent and 
I was glad to see that this group is in the growing band 
of investigators who have two guidelines. The diagram- 
matic representations of susceptible and resistant popu- 
lations are excellent and it should be apparent to all 
from these diagrams just what ‘intermediate’ means. 
Table 1 is a good model for providing simple accurate 
information to antibiotic users. The article by Sirot, 
Courvalin and Soussy (p. S5) is also an excellent demon- 
stration of how science should be applied to practical 
everyday procedures in the &agnostic clinical laboratory. 
I was therefore very disappointed that so little 
attention had been given to these papers in the 1996 
Statement on Breakpoints (p. S46). The ‘sensitive’ 
breakpoint for many antibiotics has not been related to 
the normal susceptible population of bacteria. Mode 
MICs are often greatly below the chosen breakpoint, 
so that many strains with low-level resistance are called 
‘fully susceptible’, e.g. to aztreonam, many of the 
cephalosporins and the quinolones. This is because 
the susceptible level has been based on pharmacology 
and not on microbiology (see p. S8). These problems 
become greater if they are applied to more fastidious 
species as exemplified in your footnote 2 (on p. S48) 
regarding Streptococcus pneumoniae. Application of micro- 
biological criteria to microbiological tests give a good 
definition of ‘sensitive’ ii la Goldstein et al. The pharm- 
acologic data should only be applied to defining the 
resistant population. All the other strains are inter- 
mediate. 
A lot of time has been spent trying to simplify 
interpretations of susceptibility testing. I am glad that 
you are adding so many qualifications to the tables. The 
area of susceptibility testing is complex, and the 
exceptions to the rules are many. A move towards 
species-specific guidelines applied to a limited range of 
relevant antibiotics would provide greater clarity and 
fewer exceptions. 
Thank you for your stimulating supplement, w h c h  
1 hope is studied carefully by all those carrying out the 
millions of susceptibility tests performed every day. 
John David Williams 
7 Wiham Road, 
London NW1 3ER. UK 
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